HealthCare Royalty Revenue and Competitors

HealthCare Royalty (\HCRx\) is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. HCRx has invested $5+ billion in more than 85 biopharma products since inception and has offices in Stamford (CT), San Francisco, Boston and London. The HCRx team consists of 33 individuals (including our Senior Advisors), including former pharmaceutical executives, scientists, physicians, bankers, research analysts and consultants. \n\nOur philosophy is simple - We are asset-focused investors seeking to identify compelling investment opportunities that will generate long-term value. We target healthcare assets with significant clinical value and strong barriers to entry that are meaningful to their marketer. We also look for assets that will produce sustainable revenues over an extended period of time. Our investments span the pharmaceutical, biotechnology and specialty pharmaceuticals sectors.\n\nOur investment platform is designed to serve as a long-term capital resource for our partners; flexible and directly aligned with their business models and objectives. Our team utilizes multiple investment approaches to help our partners achieve their goals including: customized debt, royalty monetization, and revenue participation financings. Since 2003, HCRx's senior professionals have completed more than 60 healthcare investments.\n\nHEALTHCARE ROYALTY® IS A REGISTERED TRADEMARK OF HEALTHCARE ROYALTY MANAGEMENT, LLC.